Creyon Bio, a San Diego biotech developing nucleic acid drugs, landed a licensing and multi-target research deal with Eli Lilly worth up to $1 billion.
Why it matters: The deal comes as Creyon seeks $15 million to $20 million in Series A extension funding, CEO Serge Messerlian tells Axios.
